• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

CardioCell reports Phase IIa heart failure data

August 30, 2016

News


Aug 30, 2016

CardioCell reports Phase IIa heart failure data

BioCentury
Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety endpoint and several secondary efficacy endpoints in a single-blind Phase IIa trial to treat chronic heart failure (CHF) in patients with non-ischemic cardiomyopathy. READ FULL ARTICLE

Media Coverage,  News

Reader Interactions

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in